GenMark Diagnostics, Inc. (NASDAQ: GNMK) announced that it has appointed Ms. Sue Pierce as Vice President, Product Development, effective April 18, 2011. Ms. Pierce joins the company with extensive diagnostics experience including over 11 years at Ventana Medical Systems (a division of Roche Diagnostics) and over 14 years at Abbott Laboratories. Most recently, Ms. Pierce was Vice President, Project Management Office in charge of all product development and program management processes across Ventana’s product portfolio. Prior to that she held the role of VP/Sr. Director, Integration and Technical Support, where she developed and led a customer-focused Global Product Technical Support function as well as led the R&D integration activities for the Roche acquisition. She was also previously Director, Product Development where she was responsible for numerous product development and system integration teams, as well as the Design Control team lead for re-engineering and implementation of a new quality system. While at Abbott Laboratories, Ms. Pierce held roles of increasing responsibility in Abbott’s Diagnostics Division, in Clinical Chemistry, Immunochemistry, and Systems Integration functions. Prior to Abbott Laboratories, she held various R&D and Operations technical positions at Celanese Corporation. Ms. Pierce has a BS in Chemistry and an MS in Analytical Chemistry, both from Oklahoma State University. "We are very pleased to welcome Sue to the GenMark team," said Chris Gleeson, GenMark's Chairman and CEO. "She brings a wealth of extensive and successful product development experience, a key ingredient at this stage of implementing GenMark’s high growth strategy." About GenMark Diagnostics, Inc. GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology. GenMark's XT-8 System is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. GenMark has developed five diagnostic tests for use with the XT-8 System, including its Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test which have received clearance from the Food and Drug Administration.
Safe Harbor StatementThis press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our growth strategy, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, and regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the "Risk Factors" in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.